A Pilot Randomized Controlled Trial for Antibiotic Exposure in Neonatal Sepsis Using Neutrophil CD64

NCT01825421 | Withdrawn

• 1 other identifier: 1212011184
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

Unnecessary and prolonged antibiotic therapy in newborn babies can have serious consequences including development of necrotizing enterocolitis (a serious, potentially life-threatening gastrointestinal illness in premature babies), late-onset infections, resistance to antibiotics, increased length of hospital stay, and death. Starting and continuing antibiotic therapy for blood culture-negative infections in the neonatal intensive care unit (NICU) is fairly common with numbers of such patients varying from 20%-90% of infants undergoing a sepsis evaluation in the NICU. While blood culture results are the gold standard, there is usually a delay of up to 48-72h before the results are known. Hence, initiation and continuation of antibiotic treatment are usually based on clinical evaluation and blood count criteria which do not possess high specificity or sensitivity, and may be unreliable in the first few hours after birth or in the early stages of infection. Since the investigators found that neutrophil CD64 (a type of protein found on the surface of a type of white blood cell that can be detected quickly in a very small amount of blood sample) has high accuracy for early detection of blood culture-proven infections in newborn babies, with extremely high negative predictive value (can identify babies definitively with no infection), the investigators will use this test to decide whether to stop or continue antibiotics in the NICU. The investigators hypothesis is that neutrophil CD64 values can be safely used to discontinue antibiotics in newborns suspected of having infections. The investigators aims are to utilize sequential measurements of CD64 values to stop antibiotics early in neonates being investigated for both early and late-onset infections in the NICU. This is a prospective, randomized, controlled (RCT) trial. The study population will be derived from the sub-set of all newborn infants who have undergone investigations for presence of infection in the NICU.

Conditions

Neonatal Early-onset Sepsis; Neonatal Late-onset Sepsis

Keywords

Infant; Infection; Newborn; Antibiotics; Neutrophil CD64; Blood Culture

Outcome Measures

Primary Outcomes (1)

• Number of infants with early-onset sepsis (EOS) and late-onset sepsis (LOS) randomized to either stopping or continuing antibiotics at 24h, based on the neutrophil CD64 measurement

  At 48h after initiation of antibiotics.

Secondary Outcomes (1)

• Change in the Neutrophil CD64 Index value in neonates with/without exposure to antibiotics from 24h to 48h.

  At 48h after initiation of antibiotics.

Other Outcomes (1)

• Number of positive blood cultures in neonates from 24h to 48h with/without exposure to antibiotics.

  At 48h after initiation of antibiotics.

Study Arms (2)

Control (continue antibiotics) group

NO INTERVENTION

The antibiotics will be continued for at least another 24h i.e. for 48h, pending blood culture results at 48h, as per standard practice in the NICU.

Study (discontinue antibiotics) group

ACTIVE COMPARATOR

The intervention is to discontinue antibiotics at 24h, and he/she will be kept under observation in the NICU for at least an additional 24h, pending blood culture results at 48h.

Other: Intervention is to stop antibiotics at 24h .

Interventions

Intervention is to stop antibiotics at 24h . OTHER

Stoppage of antibiotics at 24h in the intervention arm, randomization based on neutrophil CD64 values.

Study (discontinue antibiotics) group

Eligibility Criteria

• Age: 1 Hour - 5 Months
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Infants undergoing a sepsis evaluation in the NICU

You may not qualify if:

• They have a major life-threatening congenital malformation
• The attending neonatologist has objections to the infant participating in the study

Sponsors & Collaborators

• Yale University: lead

Study Sites (1)

Yale-New Haven Children's Hospital NICU

New Haven, Connecticut, 06520, United States

Location

MeSH Terms

Conditions

Neonatal Sepsis; Infections

Condition Hierarchy (Ancestors)

Sepsis; Infant, Newborn, Diseases; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Systemic Inflammatory Response Syndrome; Inflammation; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 2, 2013
• First Posted: April 5, 2013
• Study Start: October 1, 2014
• Primary Completion: January 1, 2016
• Study Completion: June 1, 2016
• Last Updated: March 30, 2020

Record last verified: 2015-07

Locations

US (1)